BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22461374)

  • 1. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.
    Duns G; Hofstra RM; Sietzema JG; Hollema H; van Duivenbode I; Kuik A; Giezen C; Jan O; Bergsma JJ; Bijnen H; van der Vlies P; van den Berg E; Kok K
    Hum Mutat; 2012 Jul; 33(7):1059-62. PubMed ID: 22461374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L; Testa JR; Yang H
    Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
    Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
    Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of clear-cell renal cell carcinoma.
    Brugarolas J
    J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
    Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
    Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
    Gao W; Li W; Xiao T; Liu XS; Kaelin WG
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.
    Simon JM; Hacker KE; Singh D; Brannon AR; Parker JS; Weiser M; Ho TH; Kuan PF; Jonasch E; Furey TS; Prins JF; Lieb JD; Rathmell WK; Davis IJ
    Genome Res; 2014 Feb; 24(2):241-50. PubMed ID: 24158655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling Renal Cell Carcinoma in Mice:
    Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
    Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
    Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
    Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.
    Walton J; Lawson K; Prinos P; Finelli A; Arrowsmith C; Ailles L
    Nat Rev Urol; 2023 Feb; 20(2):96-115. PubMed ID: 36253570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
    Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
    Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.